|
Together we can make it better!
New medicines and vaccines improve and save lives while reducing hospitalization, surgery and other health costs. Federal and provincial governments in Canada have been working to improve access and choice but important gaps persist. By working together, we can make Canada a world leader in giving Canadians access to innovative new medicines and vaccines to prevent and treat a wide range of diseases. The 2010-2011 Rx&D IRAM report aims to promote a discussion with our health partners about the challenges we face to build the sustainable health care systems we need.
Despite the benefits of new medicines for people to improve health care outcomes and help sustain our health care system, IRAM has consistently shown that Canada's public drug plans provide less access to new medicines compared to almost all other developed nations.
The 2010-2011 IRAM Report proposes several principals that could form the basis for a public dialogue to provide better access to innovative health care options.
On average, 48% of CDR-reviewed drugs/indications and cancer drugs/indications are publicly listed in Canada, as at July 31, 2011. When looking at the chart above, we see that the reimbursement percentage for the 31 other OECD countries is 83.5%. The range goes from a low of just above 30% in Estonia to a high of 100% in 6 OECD countries.
|
